Subscribe
E-Paper
 |
| Genome & Company CEO Pae Ji-soo |
According to the company, it will attend the event and have partnering meetings with more than 10 global drug makers from Europe, Asia and North America.
BIO-Europe is one of the largest events in the biotechnology industry, and more than 50 multinational drug makers attend every year to look for new partners and sign licensing deals for candidate drugs.
The annual event has been taking place since 1995 and this year's edition will be held online from Oct. 26 to 29 (European Standard Time) due to the COVID-19 pandemic.
During the event, Genome & Company will showcase its pipeline technology for immune checkpoint inhibitors.
Immune checkpoints differentiate between cancer cells and normal ones so the immune system can attack only the former and is prevented from destroying healthy cells. Cancer cells, however, sometimes target these checkpoints to avoid being attacked by the immune system, thus immune checkpoint inhibitors release a natural brake on the immune system so its cells can recognize and attack tumor cells.
Since the treatment does not artificially boost a patient's immunity, Genome & Company said the checkpoint inhibitors are relatively safe from side effects.
While well-known immune checkpoint inhibitors target PD-1 or PD-L1 antibodies, Genome & Company said its immune checkpoint inhibitor pipeline is aimed at exploring novel targets.
Also during the event, the company will showcase its therapeutic candidates based on microbiomes.
"Already a number of global drug makers have shown interest in Genome & Company's pipeline," said CEO Pae Ji-soo. "We expect BIO-Europe 2020 will be a stage for us to expand our network with global drug makers and build partnerships with them."
